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black, less educated, having difficulty taking their medications, female and with more
advance NYHA class. Screening such HF patients and providing greater education may
enhance their ability to participate in actively managing their HF.
11:00 a.m.
889-3 Estimating Life-Years Lost Due to Atherothrombotic 
Events: Flexible Survival Functions for Use in Disease 
Modeling
J. Jaime Caro, Kristen Migliaccio-Walle, K. Jack Ishak, William S. Weintraub, Caro 
Research Institute, Concord, MA, Emory University, Atlanta, GA
Background: The cost-effectiveness of new interventions is of growing importance.
Researchers must now translate trial findings to costs per life year gained to enable com-
parability, making proper estimation of survival after a morbid event an essential task.
This analysis must account for the patterns of events observed in the trial.
Methods: Records of all acute myocardial infarctions (MI) occurring in Saskatchewan
during the years 1990-1995 were obtained. Patient characteristics and medical history
were available from January 1980; follow-up was complete to December 2000. Functions
were fit to observed, time-dependent, mortality hazards for: all patients, acutely non-fatal
atherothrombotic event, or no subsequent event. The resulting survival curves were inte-
grated to obtain the mean survival; life years lost due to additional events were derived by
subtracting the pattern-specific life expectancy from that of no events.
Results: Over the mean 5.1 years of follow-up, 49% of the 15,590 patients (64% male;
mean age 69 years; 24% diabetic; 30% previous MI or stroke; 61% hypertensive) died. In
the first 9 months, 5% suffered a non-fatal MI, 1% a non-fatal stroke, and 72% had no
non-fatal events. The hazard functions indicate high risk of death immediately following
the index MI, but risks drop sharply as time passes without an event. Subsequent events
lead to renewed risk. The integrated survival curves reveal the impact of additional
events. For example, a 65 year-old man has a life expectancy of 9.6 years immediately
after an MI. This increases to 10.8 years if he survives the first week and to 11.7 years if
he survives through 9 months with no further events; 4.4 years are lost if a second MI
occurs, 7.2 years with a stroke.
Conclusion: These techniques yielding detailed survival functions enable researchers to
avoid the inaccuracies introduced by using average, unadjusted, life expectancies from
non-specific populations. They allow extensive customization to obtain life-years lost for
any pattern of events in any given population. A second MI or a stroke is associated with
a continuing increased hazard of death, even if not immediately fatal, and must be con-
sidered in economic analyses.
11:15 a.m.
889-4 Cost-Effectiveness of Carvedilol Versus Metoprolol 
Tartrate for Patients With Heart Failure
Paul A. Heidenreich, VA Palo Alto Health Care System, Palo Alto, CA, Stanford 
University, Stanford, CA
The Carvedilol or Metoprolol European Trial in Patients With Chronic Heart Failure
(COMET) observed a mortality benefit for carvedilol over metoprolol tartrate. However,
the cost-effectiveness of carvedilol is unclear.
Methods: We used a Markov model to simulate lifetime outcome and cost of care using
COMET data. The age of the cohort was 62 years and 80% were male. Carvedilol
improved survival (hazard ratio for death 0.87) but was assumed to increase drug cost by
$1,062 per year. Per COMET, we assumed no difference in hospitalizations. The model
used societal perspective, costs adjusted to 2002 dollars, and a discount rate of 3%. Sur-
vival was calculated as both life years and quality adjusted life years (QALYs) using a
time-tradeoff utility of 0.71 for symptomatic heart failure.
Results: Carvedilol treatment increased the lifetime discounted cost of care by $10,330
and discounted survival by 0.73 years, (0.52 QALYs). The incremental cost-effectiveness
of carvedilol was $14,240 per life-year gained ($20,050 per QALY gained). Carvedilol
remained economically attractive even if the benefit did not persist following the end of
the trial (5 years, Figure). If the benefit of carvedilol in women is as reported by COMET
(hazard ratio 0.97) then carvedilol is less economically attractive ($66,830 per life year
gained, $93,80 per QALY gained).
Conclusion: Compared to metoprolol tartrate, carvedilol improves outcome for heart fail-
ure patients at a cost that is less than other commonly accepted medical treatments. 
11:30 a.m.
889-5 Looking Proximally to Understand Distal Outcomes: 
Gender Differences in Mortality After Acute Myocardial 
Infarction
Padma Kaul, Cynthia M. Westerhout, Wei-ching Chang, Paul W. Armstrong, University of 
Alberta, Edmonton, AB, Canada
Background: Conventional population studies examining possible gender bias in pro-
cess of care and outcomes of acute myocardial infarction (AMI) have been restricted to
the inpatient setting. To be comprehensive, these evaluations should ideally incorporate
more proximal care, i.e., at presentation to the emergency department (ED).
Methods: Between April 1998 and March 2000, 5309 (3622 Males; 1687 Females) resi-
dents of Alberta, Canada presented to hospital EDs with a primary diagnosis of AMI
(ICD-9-CM 410.xx).
Results: AMI patients (pts) who died in the ED (n=213) or who were not admitted
(n=406) accounted for 12% of the population and 29% of 1-year deaths (Figure). One-
year cardiovascular (re) admission rates were 48% among the AMI cohort initially admit-
ted and 30% among those discharged from the ED (p<0.01). Among AMI pts who did not
die in the ED, women were older (median age 72 y vs. 63 y among males, p<0.01); were
more likely to be discharged (9.5% vs. 7.3%, p<0.01); received fewer cardiac procedures
by 1-year; and had higher 1-year mortality (18.1% vs. 11.7% p<0.01). However, the dif-
ference in mortality disappeared after accounting for age (p=0.89)
Conclusion: Our examination at a more proximal point of care (ED) identifies a key high-
risk segment of the population accounting for 29% of AMI deaths. Future analyses
should therefore incorporate pts who died in the ED and those who were discharged. The
finding of higher rate of discharge of women with AMI from the ED is intriguing and
deserves further exploration.
11:45 a.m.
889-6 A Simple Model Using the MUSTT Database Can Stratify 
Total Mortality and Sudden Death Risk of Coronary 
Disease Patients
Alfred E. Buxton, Kerry L. Lee, Gail E. Hafley, Eric N. Prystowsky, Mark E. Josephson, 
John D. Fisher, Michael R. Gold, The MUSTT Investigators, Brown Medical School, 
Providence, RI, Duke Clinical Research Center, Durham, NC
Background:Many factors besides ejection fraction (EF) impact on prognosis of patients
(pts) with coronary disease (CAD). We reasoned that consideration of multiple parame-
ters should enable more precise risk stratification of CAD pts considered for defibrillator
(ICD) implantation for primary prevention of sudden death.
Methods: Using a Cox model we found 24 noninvasive and invasive parameters that influ-
enced total mortality (TM) and arrhythmic death or cardiac arrest (AD/CA) in all 1791
patients enrolled in the Multicenter Unsustained Tachycardia Trial (MUSTT) who did not
receive antiarrhythmic therapy. Five factors had the greatest impact on events: digitalis
use at time of enrollment, discovery of nonsustained ventricular tachycardia (NSVT) >10
days after bypass surgery (CABG), EF <=30%, Age >=65 years, presence of IVCD or
